Skip to main content
Top
Published in: Journal of Neurology 3/2011

Open Access 01-03-2011 | Original Communication

Early atrophy of pallidum and accumbens nucleus in Huntington’s disease

Authors: Simon J. A. van den Bogaard, Eve M. Dumas, Tanka P. Acharya, Hans Johnson, Douglas R. Langbehn, Rachael I. Scahill, Sarah J. Tabrizi, Mark A. van Buchem, Jeroen van der Grond, Raymund A. C. Roos, TRACK-HD Investigator Group

Published in: Journal of Neurology | Issue 3/2011

Login to get access

Abstract

In Huntington’s disease (HD) atrophy of the caudate nucleus and putamen has been described many years before clinical manifestation. Volume changes of the pallidum, thalamus, brainstem, accumbens nucleus, hippocampus, and amygdala are less well investigated, or reported with contradicting results. The aim of our study is to provide a more precise view of the specific atrophy of the subcortical grey matter structures in different stages of Huntington’s disease, and secondly to investigate how this influences the clinical manifestations. All TRACK-HD subjects underwent standardised T1-weighted 3T MRI scans encompassing 123 manifest HD (stage 1, n = 77; stage 2, n = 46), 120 premanifest HD (close to onset n = 58, far from onset n = 62) and 123 controls. Using FMRIB’s FIRST and SIENAX tools the accumbens nucleus, amygdala, brainstem, caudate nucleus, hippocampus, pallidum, putamen, thalamus and whole brain volume were extracted. Results showed that volumes of the caudate nucleus and putamen were reduced in premanifest HD far from predicted onset (>10.8 years). Atrophy of accumbens nucleus and pallidum was apparent in premanifest HD in the close to onset group (0–10.8 years). All other structures were affected to some degree in the manifest group, although brainstem, thalamus and amygdala were relatively spared. The accumbens nucleus, putamen, pallidum and hippocampus had a strong significant correlation with functional and motor scores. We conclude that volume changes may be a sensitive and reliable measure for early disease detection and in this way serve as a biomarker for Huntington’s disease. Besides the caudate nucleus and putamen, the pallidum and the accumbens nucleus show great potential in this respect.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aylward EH (2007) Change in MRI striatal volumes as a biomarker in preclinical Huntington’s disease. Brain Res Bull 72:152–158PubMedCrossRef Aylward EH (2007) Change in MRI striatal volumes as a biomarker in preclinical Huntington’s disease. Brain Res Bull 72:152–158PubMedCrossRef
2.
go back to reference Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ (1994) Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology 44(5):823–828PubMed Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ (1994) Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology 44(5):823–828PubMed
3.
go back to reference Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J (1996) Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 53:1293–1296PubMed Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J (1996) Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 53:1293–1296PubMed
4.
go back to reference Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, Barta PE, Pearlson GD, Ross CA (2000) Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord 15:552–560PubMedCrossRef Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, Barta PE, Pearlson GD, Ross CA (2000) Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord 15:552–560PubMedCrossRef
5.
go back to reference Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA (2004) Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63:66–72PubMed Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA (2004) Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63:66–72PubMed
6.
go back to reference Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L (1997) Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain 120(Pt 12):2207–2217PubMedCrossRef Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L (1997) Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain 120(Pt 12):2207–2217PubMedCrossRef
7.
go back to reference Campodonico JR, Aylward E, Codori AM, Young C, Krafft L, Magdalinski M, Ranen N, Slavney PR, Brandt J (1998) When does Huntington’s disease begin? J Int Neuropsychol Soc 4:467–473PubMedCrossRef Campodonico JR, Aylward E, Codori AM, Young C, Krafft L, Magdalinski M, Ranen N, Slavney PR, Brandt J (1998) When does Huntington’s disease begin? J Int Neuropsychol Soc 4:467–473PubMedCrossRef
8.
go back to reference Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C, Krystkowiak P, Damier P, Bachoud-Levi AC, Hantraye P, Remy P (2006) Distribution of grey matter atrophy in Huntington’s disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 32:1562–1575PubMedCrossRef Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C, Krystkowiak P, Damier P, Bachoud-Levi AC, Hantraye P, Remy P (2006) Distribution of grey matter atrophy in Huntington’s disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 32:1562–1575PubMedCrossRef
9.
go back to reference Estrada Sanchez AM, Mejia-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Arch Med Res 39:265–276PubMedCrossRef Estrada Sanchez AM, Mejia-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Arch Med Res 39:265–276PubMedCrossRef
10.
go back to reference Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J (1999) Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington’s disease. Brain 122(Pt 9):1667–1678PubMedCrossRef Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J (1999) Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington’s disease. Brain 122(Pt 9):1667–1678PubMedCrossRef
11.
go back to reference Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, Chase GA, Folstein SE (1992) Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann Neurol 31:69–75PubMedCrossRef Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, Chase GA, Folstein SE (1992) Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann Neurol 31:69–75PubMedCrossRef
12.
go back to reference Henley SM, Frost C, Macmanus DG, Warner TT, Fox NC, Tabrizi SJ (2006) Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 67:694–696PubMedCrossRef Henley SM, Frost C, Macmanus DG, Warner TT, Fox NC, Tabrizi SJ (2006) Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 67:694–696PubMedCrossRef
13.
go back to reference Jernigan TL, Salmon DP, Butters N, Hesselink JR (1991) Cerebral structure on MRI, Part II: Specific changes in Alzheimer’s and Huntington’s diseases. Biol Psychiatry 29:68–81PubMedCrossRef Jernigan TL, Salmon DP, Butters N, Hesselink JR (1991) Cerebral structure on MRI, Part II: Specific changes in Alzheimer’s and Huntington’s diseases. Biol Psychiatry 29:68–81PubMedCrossRef
14.
go back to reference Jurgens CK, Van de Wiel WL, van Es AC, Grimbergen YM, Witjes-Ane MN, der van GJ, Middelkoop HA, Roos RA (2008) Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease. J Neurol 255:1785–1791PubMedCrossRef Jurgens CK, Van de Wiel WL, van Es AC, Grimbergen YM, Witjes-Ane MN, der van GJ, Middelkoop HA, Roos RA (2008) Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease. J Neurol 255:1785–1791PubMedCrossRef
15.
go back to reference Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB (2005) Thalamic atrophy in Huntington’s disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 15:846–853PubMedCrossRef Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB (2005) Thalamic atrophy in Huntington’s disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 15:846–853PubMedCrossRef
16.
go back to reference Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB (2004) Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 75:213–220PubMed Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB (2004) Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 75:213–220PubMed
17.
go back to reference Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA (2005) Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 76:650–655PubMedCrossRef Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA (2005) Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 76:650–655PubMedCrossRef
18.
go back to reference Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004) A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 65:267–277PubMedCrossRef Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004) A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 65:267–277PubMedCrossRef
19.
go back to reference Langbehn DR, Hayden MR, Paulsen JS (2009) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet Langbehn DR, Hayden MR, Paulsen JS (2009) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet
20.
go back to reference Muhlau M, Gaser C, Wohlschlager AM, Weindl A, Stadtler M, Valet M, Zimmer C, Kassubek J, Peinemann A (2007) Striatal gray matter loss in Huntington’s disease is leftward biased. Mov Disord 22:1169–1173PubMedCrossRef Muhlau M, Gaser C, Wohlschlager AM, Weindl A, Stadtler M, Valet M, Zimmer C, Kassubek J, Peinemann A (2007) Striatal gray matter loss in Huntington’s disease is leftward biased. Mov Disord 22:1169–1173PubMedCrossRef
21.
go back to reference Patenaude B (2007) Bayesian statistical models of shape and appearance for subcortical brain segmentation Patenaude B (2007) Bayesian statistical models of shape and appearance for subcortical brain segmentation
22.
go back to reference Patenaude B, Smith S, Kennedy D, Jenkinson M (2007) FIRST - FMRIB’s integrated registration and segmentation tool Patenaude B, Smith S, Kennedy D, Jenkinson M (2007) FIRST - FMRIB’s integrated registration and segmentation tool
23.
go back to reference Patenaude B, Smith S, Kennedy D, Jenkinson M (2008) Improved Surface Models for FIRST Patenaude B, Smith S, Kennedy D, Jenkinson M (2008) Improved Surface Models for FIRST
24.
go back to reference Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E (2006) Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 63:883–890PubMedCrossRef Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E (2006) Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 63:883–890PubMedCrossRef
25.
go back to reference Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880PubMedCrossRef Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880PubMedCrossRef
26.
go back to reference Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J (2005) Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 239:11–19PubMedCrossRef Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J (2005) Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 239:11–19PubMedCrossRef
27.
go back to reference Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41:689–692PubMedCrossRef Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41:689–692PubMedCrossRef
28.
go back to reference Roos RAC (1986) Neuropathology of Huntington’s chorea. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of Clinical Neurology; Extrapyramidal Disorders. Elsevier Science Publishers, Amsterdam Roos RAC (1986) Neuropathology of Huntington’s chorea. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of Clinical Neurology; Extrapyramidal Disorders. Elsevier Science Publishers, Amsterdam
29.
go back to reference Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65:745–747PubMedCrossRef Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65:745–747PubMedCrossRef
30.
go back to reference Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60:1615–1620PubMed Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60:1615–1620PubMed
31.
go back to reference Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B (2002) Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology 58:695–701PubMed Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B (2002) Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology 58:695–701PubMed
32.
go back to reference Roze E, Saudou F, Caboche J (2008) Pathophysiology of Huntington’s disease: from huntingtin functions to potential treatments. Curr Opin Neurol 21:497–503PubMedCrossRef Roze E, Saudou F, Caboche J (2008) Pathophysiology of Huntington’s disease: from huntingtin functions to potential treatments. Curr Opin Neurol 21:497–503PubMedCrossRef
33.
go back to reference Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F (2008) Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 79:130–135PubMedCrossRef Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F (2008) Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 79:130–135PubMedCrossRef
34.
go back to reference Ruocco HH, Lopes-Cendes I, Li LM, Santos-Silva M, Cendes F (2006) Striatal and extrastriatal atrophy in Huntington’s disease and its relationship with length of the CAG repeat. Braz J Med Biol Res 39:1129–1136PubMedCrossRef Ruocco HH, Lopes-Cendes I, Li LM, Santos-Silva M, Cendes F (2006) Striatal and extrastriatal atrophy in Huntington’s disease and its relationship with length of the CAG repeat. Braz J Med Biol Res 39:1129–1136PubMedCrossRef
35.
go back to reference Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29:1–3PubMed Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29:1–3PubMed
36.
go back to reference Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25:466–475PubMedCrossRef Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25:466–475PubMedCrossRef
37.
go back to reference Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23(Suppl 1):S208–S219PubMedCrossRef Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23(Suppl 1):S208–S219PubMedCrossRef
38.
go back to reference Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489PubMedCrossRef Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489PubMedCrossRef
39.
go back to reference Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol
40.
go back to reference Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS (2002) The distribution of structural neuropathology in pre-clinical Huntington’s disease. Brain 125:1815–1828PubMedCrossRef Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS (2002) The distribution of structural neuropathology in pre-clinical Huntington’s disease. Brain 125:1815–1828PubMedCrossRef
Metadata
Title
Early atrophy of pallidum and accumbens nucleus in Huntington’s disease
Authors
Simon J. A. van den Bogaard
Eve M. Dumas
Tanka P. Acharya
Hans Johnson
Douglas R. Langbehn
Rachael I. Scahill
Sarah J. Tabrizi
Mark A. van Buchem
Jeroen van der Grond
Raymund A. C. Roos
TRACK-HD Investigator Group
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 3/2011
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5768-0

Other articles of this Issue 3/2011

Journal of Neurology 3/2011 Go to the issue